Article
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
PloS one - 1 Jan 2022
Uchida Yoshihito, Nakao Masamitsu, Yamada Shunsuke, Tsuji Shohei, Uemura Hayato, Kouyama Jun-Ichi, Naiki Kayoko, Sugawara Kayoko, Nakayama Nobuaki, Imai Yukinori, Tomiya Tomoaki, Mochida Satoshi
Abstract excerpt
BACKGROUND: To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. METHODS: A total of 103 patients with serum HBsAg levels of ≥100 IU/mL who had received ETV were enrolled. The nucleos(t)ide analog used for the treatment was switched from ETV to TAF, and the changes in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.